Skip to main content
Equibles
EDIT logo

EDIT · Editas Medicine, Inc. · Webcasts, Transcripts & Audio

Track EDIT — free

Use EDIT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EDIT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.62 +0.10 (+3.97%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$396.24M
Shares
153.58M
Volume · Oct 2 2.16M Avg daily vol (3M) 2.47M

Editas Medicine, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Editas Medicine, Inc. (EDIT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1578.6% $6.36M −$53.45M '22 Q2 22-08-03 ▼99.3% $42,000 −$55.73M '22 Q3 22-11-02 ▼47.6% $6.54M −$60.74M '22 Q4 23-02-22 ▲45.5% $9.85M −$49.04M '23 Q1 23-05-05 ▼54.6% $2.89M −$40.29M '23 Q2 23-08-02 ▲12604.8% $5.34M −$45.02M '23 Q3 23-11-03 ▲818.6% $60.05M −$18.87M '23 Q4 24-02-28 ▼88.5% $1.14M −$61.95M '24 Q1 24-05-08 ▼82.2% $513,000 −$67.61M '24 Q2 24-08-07 ▼98.9% $61,000 −$62.14M '24 Q3 24-11-04 ▼49% $30.61M −$45.40M '24 Q4 25-01-13 ▲310.4% $4.66M −$76.09M '25 Q1 25-05-12 ▲597.5% $3.58M −$53.23M '25 Q2 25-09-02 ▲12265.6% $7.54M −$25.12M '25 Q3 25-11-10 ▼19.2% $24.74M −$5.62M '25 Q4 26-03-09 LATEST ▼39.2% $2.83M −$24.98M '26 Q1 26-05-05
Conference
Investor event
2026-06-04
Editas Medicine, Inc. (EDIT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Editas Medicine, Inc. (EDIT) Q1 2026 Earnings Call
Revenue
$2.83M
▼ 39.2% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-12
Editas Medicine, Inc. (EDIT) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-09
Editas Medicine, Inc. (EDIT) Q4 2025 Earnings Call
Revenue
$24.74M*
▼ 19.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Editas Medicine, Inc. (EDIT) Q3 2025 Earnings Call
Revenue
$7.54M
▲ 12265.6% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-09-02
Editas Medicine, Inc. (EDIT) Q2 2025 Earnings Call
Revenue
$3.58M
▲ 597.5% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Editas Medicine, Inc. (EDIT) Q1 2025 Earnings Call
Revenue
$4.66M
▲ 310.4% YoY
Diluted EPS
$-0.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Editas Medicine, Inc. (EDIT) Q4 2024 Earnings Call
Revenue
$30.61M*
▼ 49% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Editas Medicine, Inc. (EDIT) Q3 2024 Earnings Call
Revenue
$61,000
▼ 98.9% YoY
Diluted EPS
$-0.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript
Positive tone Reni-cel Clinical Progress (RUBY/EdiTHAL) In-Vivo Gene Editing Pipeline Enrollment and BLA Path
Revenue
$513,000
▼ 82.2% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
Confident tone Reni-cel clinical progress and enrollment In vivo gene editing pipeline Regulatory and BLA pathway
Revenue
$1.14M
▼ 88.5% YoY
Diluted EPS
$-0.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
Confident tone Reni-cel clinical development FDA regulatory alignment Enrollment and dosing progress
Revenue
$60.05M*
▲ 818.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-03
Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Call Transcript
Revenue
$5.34M
▲ 12604.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Editas Medicine, Inc. (EDIT) Q2 2023 Earnings Call Transcript
Revenue
$2.89M
▼ 54.6% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call Transcript
Revenue
$9.85M
▲ 45.5% YoY
Diluted EPS
$-0.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Editas Medicine, Inc. (EDIT) Q4 2022 Earnings Call Transcript
Revenue
$6.54M*
▼ 47.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript
Revenue
$42,000
▼ 99.3% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Editas Medicine, Inc. (EDIT) Q2 2022 Earnings Call Transcript
Revenue
$6.36M
▲ 1578.6% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Editas Medicine, Inc. (EDIT) Q1 2022 Earnings Call Transcript
Revenue
$6.77M
▲ 4.2% YoY
Diluted EPS
$-0.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Editas Medicine, Inc. (EDIT) Q4 2021 Earnings Call Transcript
Revenue
$12.47M*
▲ 9.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Editas Medicine, Inc. (EDIT) Q3 2021 Earnings Call Transcript
Revenue
$6.20M
▼ 90.1% YoY
Diluted EPS
$-0.57
▼ 575% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Editas Medicine, Inc. (EDIT) Q2 2021 Earnings Call Transcript
Revenue
$379,000
▼ 96.5% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
Revenue
$6.50M
▲ 13.6% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-19
Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
Revenue
$11.42M
▼ 7% YoY
Diluted EPS
$-1.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Editas Medicine, Inc. (EDIT) Q3 2020 Earnings Call Transcript
Revenue
$62.84M
▲ 1533.1% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Editas Medicine, Inc. (EDIT) Q2 2020 Earnings Call Transcript
Revenue
$10.75M
▲ 361.3% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Editas Medicine, Inc. (EDIT) Q1 2020 Earnings Call Transcript
Revenue
$5.72M
▲ 176.6% YoY
Diluted EPS
$-0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Editas Medicine, Inc. (EDIT) Q4 2019 Earnings Call
Revenue
$12.28M
▲ 100.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 4 filings 4 filers Visit website Investor relations